Entera Bio

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$0.52-$3.35
Market Cap
$58.5M
Shares Short
44,153

Financials

See more
Revenue (12 Mos)
$99,000
Revenue Growth (YoY)
-91.5%
Gross Profit (12 Mos)
$33,000
Diluted EPS
-$0.26

News

See more

Yahoo Finance • 12 months ago

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform

Yahoo Finance • last year

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Yahoo Finance • last year

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Yahoo Finance • last year

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

About

CEO
Ms. Miranda J. Toledano M.B.A.
Address
Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
17